当前位置: 首页 >> 检索结果
共有 61905 条符合本次的查询结果, 用时 1.4255081 秒

381. Coronary Culprit Lesion Location and Intramyocardial Hemorrhage in STEMI.

作者: Fritz Oberhollenzer.;Ivan Lechner.;Christina Tiller.;Magdalena Holzknecht.;Alex Kaser.;Philipp Fischer.;Agnes Mayr.;Felix Troger.;Axel Bauer.;Bernhard Metzler.;Sebastian J Reinstadler.;Martin Reindl.
来源: Circ Cardiovasc Imaging. 2026年19卷5期e019364页
Intramyocardial hemorrhage (IMH) is a major determinant of adverse outcome in patients with ST-segment-elevation myocardial infarction, therefore making it a promising therapeutic target. This study aimed to investigate the association between coronary culprit lesion location and IMH in acute ST-segment-elevation myocardial infarction.

382. Prognostic Utility of Perivascular Adipose Tissue Attenuation in Patients Undergoing Endovascular Aneurysm Repair for Abdominal Aortic Aneurysms.

作者: Koshi Matsuhama.;Takayoshi Toba.;Yoichiro Sugizaki.;Tatsuya Kitagawa.;Shotaro Yoshida.;Mayuka Masuda.;Keisuke Iida.;Ken Takata.;Nobuhiro Watanabe.;Kotaro Higuchi.;Hiroya Okamoto.;Yuta Fukuishi.;Yuki Sakamoto.;Shota Naniwa.;Hiroshi Tsunamoto.;Tetsuya Yamamoto.;Seigo Iwane.;Yuto Osumi.;Daichi Fujimoto.;Takashi Hiromasa.;Hiroyuki Kawamori.;Hironaga Shiraki.;Taishi Inoue.;Katsuhiro Yamanaka.;Hiroaki Takahashi.;Tomoyuki Gentsu.;Koji Sasaki.;Masato Yamaguchi.;Kenji Okada.;Hiromasa Otake.
来源: Circ Cardiovasc Imaging. 2026年19卷5期e019185页
Perivascular adipose tissue (PVAT) attenuation on computed tomography angiography reflects vascular inflammation. However, its prognostic value in patients undergoing endovascular aortic repair (EVAR) for abdominal aortic aneurysm (AAA) remains unclear.

383. Advancing Women's Health Through Public Policy.

作者: Stacey E Rosen.;Amit Khera.;Janay C Johnson.
来源: Circulation. 2026年153卷17期1340-1342页

384. Letter by Rose Regarding Article, "Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis".

作者: David Rose.
来源: Circulation. 2026年153卷17期e1151-e1152页

385. Response by Kang to Letter Regarding Article, "Long-Term Outcomes of Early Surgery versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis".

作者: Duk-Hyun Kang.
来源: Circulation. 2026年153卷17期e1153页

386. Effect of Empagliflozin on Device-Measured Thoracic Impedance in Patients With Type 2 Diabetes Treated With an Implantable Cardioverter Defibrillator.

作者: Takayuki Sumiyoshi.;Kenichi Iijima.;Shinya Fujiki.;Koji Hirabayashi.;Hiroki Matsumoto.;Shunsuke Kuroda.;Hidemori Hayashi.;Yoshihisa Nakagawa.;Kazuyoshi Takahashi.;Masaaki Okabe.;Kengo Kusano.;Shingen Owada.;Yusuke Kondo.;Kenichi Tsujita.;Yoshiaki Kubota.;Hirofumi Tomita.;Toshihisa Anzai.;Morio Shoda.;Masafumi Watanabe.;Takashi Tokano.;Toyoaki Murohara.;Takashi Kaneshiro.;Takeshi Kato.;Hidehira Fukaya.;Koji Maemura.;Tomio Umemoto.;Ritsushi Katou.;Takashi Saigawa.;Shigeto Naito.;Kenji Ando.;Masafumi Yano.;Junichi Nitta.;Tetsuji Miura.;Yugo Yamashita.;Kazuomi Kario.;Miyako Igarashi.;Hisako Yoshida.;Takahiro Tanaka.;Koichi Node.;Tohru Minamino.
来源: Circulation. 2026年153卷17期1343-1346页

387. A Narrow Window in a Wide Complex Rhythm.

作者: Ashwin A Pillai.;Gautham Kalahasty.;Kenneth A Ellenbogen.
来源: Circulation. 2026年153卷17期1337-1339页

388. Novel Application of a Familiar Concept: TR Proportionality and T-TEER Outcomes.

作者: Jonathan E Labin.;Serge Harb.;Grant W Reed.
来源: Circ Cardiovasc Interv. 2026年19卷6期e016819页

389. Diagnostic Yield of Exome Sequencing in Patients With Congenital Heart Disease From Southern Africa.

作者: Timothy F Spracklen.;Thomas Aldersley.;John Lawrenson.;Paul Human.;Blanche Cupido.;Fenny Shidhika.;George Comitis.;Barend Fourie.;Andre Brooks.;Lenise Swanson.;Rik De Decker.;Kélin Engel.;Alexia Joachim.;Phaphama Magadla.;Hope-Kirsten Edwards.;Karen Sliwa.;Gasnat Shaboodien.;Raj Ramesar.;Bernard D Keavney.;Liesl J Zühlke.
来源: Circ Genom Precis Med. 2026年e005463页
Congenital heart disease (CHD) is a leading cause of pediatric morbidity and mortality worldwide. The genetics of CHD in African populations is not well understood, although it has been shown in other settings that a genetic diagnosis can have implications for patient management and risk stratification. In this study, we aimed to identify pathogenic and likely pathogenic (P/LP) variants in a cohort of patients with CHD from Southern Africa.

390. Precision Antiplatelet Therapy: The Promise and Complexity of Pharmacogenomic Antiplatelet Therapy.

作者: Carine E Hamo.;Jeffrey S Berger.
来源: Circ Cardiovasc Interv. 2026年19卷5期e016678页

391. Integrated Genomic and Transcriptomic Study Reveals MAPK11 and PER1 as Important Obesity Susceptibility Genes in a High-Risk Hispanic/Latino Population.

作者: Daeeun Kim.;Hannah G Polikowsky.;Heather M Highland.;Hung-Hsin Chen.;Wanying Zhu.;Xinruo Zhang.;Madeline G Gillman.;Elizabeth G Frankel.;Rashedeh Roshani.;Joshua M Landman.;Yujie Wang.;Kristin L Young.;Mohammad Yaser Anwar.;Mohanraj Krishnan.;Victoria L Buchanan.;Sonja I Berndt.;Joshua D Arias.;Laura M Raffield.;Absalon D Gutierrez.;Faraz Bishehsari.;Miryoung Lee.;Joseph B McCormick.;Susan P Fisher-Hoch.;Jennifer E Below.;Kari E North.;Mariaelisa Graff.
来源: Circ Genom Precis Med. 2026年e005298页
While GWAS (genome-wide association studies) have identified over 1000 obesity-associated loci, their functional impact on gene expression remains unclear. Moreover, many studies have not fully captured the genetic architecture of obesity in high-risk populations or considered the complexity of adiposity beyond traditional measures. To address these gaps, this study explores the genetic and transcriptomic pathways of obesity using diverse obesity phenotypes in a high-risk population.

392. Prognostic Impact of Renal Function on Outcomes After Physiology-Guided Coronary Revascularization: Insights From the J-PRIDE Registry.

作者: Hirofumi Ohashi.;Shoichi Kuramitsu.;Hirohiko Ando.;Tomohiro Shinozaki.;Yoshiaki Kawase.;Takenori Domei.;Futoshi Yamanaka.;Umihiko Kaneko.;Tsunekazu Kakuta.;Kazunori Horie.;Hidenobu Terai.;Yasutsugu Shiono.;Toru Tagashira.;Kazutaka Nogi.;Takashi Kubo.;Taku Asano.;Jun Shiraishi.;Hiromasa Otake.;Akinori Sugano.;Hiroki Okabe.;Atsushi Iwai.;Yuetsu Kikuta.;Hidetaka Nishina.;Masashi Iwabuchi.;Hiroyoshi Yokoi.;Takashi Akasaka.;Hitoshi Matsuo.;Nobuhiro Tanaka.;Tetsuya Amano.; .
来源: Circ Cardiovasc Interv. 2026年19卷7期e016454页
The clinical utility of physiology-guided revascularization for decision-making in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains uncertain. The aim of this study is to evaluate the diagnostic performance and prognostic significance of fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs) according to the severity of CKD.

393. Subcutaneous Defibrillator Implantation With or Without Defibrillation Test: The Primary Results of the Randomized PRAETORIAN-DFT Trial.

作者: Reinoud E Knops.;Christelle Marquie.;Peter Nordbeck.;Roland R Tilz.;Leonard A Dijkshoorn.;Anne-Floor B E Quast.;Tom F Brouwer.;Pier D Lambiase.;Christopher J Cassidy.;Lucas V A Boersma.;Martin C Burke.;Timothy R Betts.;Vincent Probst.;Harish Manyam.;Frank A L E Bracke.;Hendrik Bonnemeier.;Jürgen Kuschyk.;Gregory Golovchiner.;Anouk de Weger.;Marc A Miller.;Jonas S S G de Jong.;Abdul Ghani.;Nigel Lewis.;Eloi Marijon.;Nick R Bijsterveld.;Pascal Defaye.;Claire A Martin.;Duncan C Field.;Jan Elders.;Naushad A Shaik.;Serge Boveda.;Willeke van der Stuijt.;Jolien A de Veld.;Kirsten M Kooiman.;Shari Pepplinkhuizen.;Lukas Kaiser.;Anita Arya.;Raymond Tukkie.;Léon J P M van Woerkens.;Margriet W Feenema-Aardema.;Michael Glikson.;Alexander H Maass.;Amir Zaidi.;Arthur A M Wilde.;Louise R A Olde Nordkamp.;Lonneke Smeding.;Mikhael F El-Chami.; .
来源: Circulation. 2026年154卷6期520-531页
To improve survival of patients at risk of sudden cardiac death, subcutaneous implantable cardioverter defibrillators (S-ICDs) require optimal implant positioning for effective shocks. Defibrillation (DF) testing is recommended but carries serious risks. The PRAETORIAN score predicts defibrillation outcomes on the basis of chest X-ray. The PRAETORIAN-DFT (Prospective Randomized Comparative Trial of Subcutaneous Implantable Cardioverter Defibrillator Implantation With and Without Defibrillation Testing) trial evaluated whether omission of DF testing guided by the PRAETORIAN score is noninferior for first-shock efficacy.

394. Circulatory Support Escalation in Cardiogenic Shock Outcomes and Predictors of Successful Escalation from an International, Multi-Center Cardiac Intensive Care Registry.

作者: Luca Baldetti.;Guglielmo Gallone.;Jorge A Ortega-Hernandez.;Giulio Cacioli.;Mariagiulia Festi.;Francesca Pirone.;Federica Curro Dossi.;Pier Paolo Bocchino.;Filippo Angelini.;Lorenzo Brignone.;Veronica Vitiello.;Francesco Maria Perulli.;Emilio D'Avino.;Héctor González-Pacheco.;Francesco Calvo.;Stefania Sacchi.;Marina Pieri.;Antonio Loforte.;Silvia Ajello.;Simone Frea.;Giampaolo Luzi.;Alexandra Arias-Mendoza.;Jaime A Hernandez-Montfort.;Marco Metra.;Gaetano Maria De Ferrari.;Anna Mara Scandroglio.
来源: Circ Heart Fail. 2026年
Background: Circulatory support escalation is often required during cardiogenic shock (CS) treatment. Currently, no large-scale data is available to inform how escalation strategies integrate in contemporary CS management and affect outcomes. Methods: We assessed the frequency, outcomes, and prognostic implications of escalation from a retrospective international registry of CS patients from 4 cardiac intensive care units. Escalation was defined as any incremental change in the circulatory support strategy after an initial bundle of care was established for at least 4 hours. Results: Among 602 consecutive CS patients, escalation was required in 30%. Patients were escalated to inotropes/vasopressors (36%), IABP (39%), Impella (14%) or V-A ECMO (11%). Escalation was associated with a higher hospital mortality rate (43% vs 21%; p<0.001; ORadj 3.42; 95% CI 2.21-3.35) and a greater transition to heart replacement therapies (23% vs 5%; p<0.001; ORadj 6.01; 95% CI 3.31-11.27), when adjusted for age, sex, chronic kidney disease, markers of CS severity on admission, CS etiology, and admission source. Escalation was associated with a higher risk of complications including acute kidney injury, major bleeding, and stroke. These outcomes occurred more frequently with high-profile mechanical circulatory support (Impella, V-A ECMO). Complications mediated 24% (95%CI 9-40%) of the association between escalation and hospital death. Escalated patients were successfully discharged alive in 42%. Age, SCAI B to C stage at escalation, TAPSE at escalation, and mean urinary output ≥1 mL/kg/hour in the 6 hours preceding escalation were independently associated with successful escalation when adjusted for sex, chronic kidney disease, and markers of CS severity on admission and at time of escalation. Conclusions: Circulatory support escalation is prevalent in patients treated for CS. Escalation is associated with a higher risk of hospital death, complications and transition to HRT, consistently with the intrinsically higher risk profile and expected trajectory of escalated patients. However, outcomes may differ according to the specific escalation strategy. Resorting to escalation in younger patients, in less severe CS stages, when the right ventricular function and urinary output are still preserved is associated with a higher chance of subsequent survival.

395. First-in-Human Clinical Experience With Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs.

作者: Shivaraj Patil.;Xiaoke Liu.;Konstantinos C Siontis.;Narut Prasitlumkum.;Samuel J Asirvatham.;Yong-Mei Cha.;Freddy Del-Carpio Munoz.;Abhishek J Deshmukh.;Christopher V DeSimone.;Fatima M Ezzeddine.;Paul A Friedman.;Gurukripa N Kowlgi.;Malini Madhavan.;Siva K Mulpuru.;Thomas M Munger.;Duy Nguyen.;Peter A Noseworthy.;Nicholas Y Tan.;Alan Sugrue.;Suraj Kapa.;Ammar M Killu.
来源: Circ Arrhythm Electrophysiol. 2026年19卷6期e014942页
Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit may be unsuccessful, highlighting the need for alternative approaches. We aimed to assess the efficacy and safety of a novel dual-modality focal catheter in treating left ventricular summit PVCs in patients who had failed previous RF ablation.

396. Maximizing Lesion Depth With the Lattice-Tip Catheter: A Preclinical Comparison of Single, Double, and Mixed Pulsed-Field and Radiofrequency Applications.

作者: Keita Watanabe.;Masaya Shinohara.;Fengyuan Yu.;Vivek Y Reddy.;Jacob S Koruth.
来源: Circ Arrhythm Electrophysiol. 2026年19卷5期e014799页
Combining radiofrequency (RF) and pulsed-field (PF) applications in various combinations, or repeating PF applications, has been reported to augment lesion size and depth. We compared lesion dimensions using single, double, and combined applications of PF and RF for the large-footprint lattice-tip catheter.

397. Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study.

作者: Subbaramireddy Remala.;Liming Liang.;Amil M Shah.;Leo F Buckley.
来源: Circ Genom Precis Med. 2026年e005535页
SGLT2 (sodium-glucose cotransporter-2) inhibitors and GLP-1R (glucagon-like peptide-1 receptor) agonists reduce the risk of major adverse cardiovascular and kidney events in individuals with various cardiometabolic conditions. The long-term efficacy and safety of these therapies, especially in low- and moderate-risk populations, remain uncertain.

398. Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.

作者: Deepak K Gupta.;Lynne W Stevenson.;Erica M Garner.;Christopher Maulion.;Hui Nian.;Patricia R Wright.;Adina F Turcu.;Shouzou Wei.;Nancy J Brown.
来源: Circ Heart Fail. 2026年19卷6期e014117页
Symptomatic hypotension can limit sacubitril/valsartan therapy. Neprilysin inhibition may augment vasodilators, such as bradykinin. We hypothesized that bradykinin contributes to blood pressure (BP) lowering with sacubitril/valsartan in stable ambulatory patients with heart failure and reduced ejection fraction <50%.

399. Physical Activity in Pediatric Cardiomyopathies: Moving for Health: A Scientific Statement From the American Heart Association.

作者: Jonathan B Edelson.;Carissa M Baker-Smith.;Barbara Cifra.;Melissa Cousino.;Sharlene M Day.;Jonathan A Drezner.;Anne M Dubin.;Corey Gates.;David A White.;Jennifer Conway.; .
来源: Circulation. 2026年153卷21期e1344-e1358页
Physical activity (PA) is essential for the cardiovascular, emotional, and social health of all children and adolescents. However, for pediatric patients with cardiomyopathy, decades of risk-averse clinical guidance have resulted in widespread PA restriction due to fears of sudden cardiac death and disease progression. This has contributed to sedentary behavior, poor cardiorespiratory fitness, and increased risk of secondary cardiometabolic conditions in this population. However, emerging data challenge this restrictive paradigm, showing that the risk of sudden cardiac death may not be higher in some patients with cardiomyopathy who exercise than in those who are less active, and that participation in PA may also have a positive effect on reverse remodeling. This American Heart Association scientific statement provides an evidence-based framework for the promotion of PA in pediatric patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, or arrhythmogenic cardiomyopathy, as well as those with implantable cardioverter defibrillators; outlines the physical, social, and emotional benefits of PA for these children and adolescents; and provides updated risk stratification strategies, including the use of advanced imaging, exercise testing, and genotype-specific data. This scientific statement underscores the importance of shared decision-making tailored to developmental maturity and family goals and emphasizes the need for longitudinal surveillance as clinical phenotypes evolve. With individualized assessment and informed shared decision-making, most children and adolescents with cardiomyopathy can safely engage in PA, with important implications for long-term cardiometabolic and psychologic health.

400. SIRT5 Ameliorates Cardiac Fibrosis via PCK2 Desuccinylation-Mediated Metabolic Reprogramming in Cardiac Fibroblasts.

作者: Maoxiong Wu.;Jing Tan.;Weibin Zhou.;Zenghui Zhang.;Qingyuan Gao.;Yangwei Cai.;Guanghong Liao.;Zhengyu Cao.;Chuanrui Zeng.;Yi Zhang.;Zhiteng Chen.;Qiong Qiu.;Zhaoyu Liu.;Jingfeng Wang.;Haifeng Zhang.;Yangxin Chen.
来源: Circulation. 2026年154卷3期243-264页
SIRT5 (sirtuin 5) is a member of the sirtuin family known to regulate cardiac metabolism, aging, and function. However, its role in cardiac fibroblast (CFB) metabolism, activation, and fibrosis remains elusive.
共有 61905 条符合本次的查询结果, 用时 1.4255081 秒